An indirect comparison and cost per responder analysis of adalimumab, methotrexate and apremilast in the treatment of methotrexate-naïve patients with psoriatic arthritis. [electronic resource]
Producer: 20161213Description: 721-9 p. digitalISSN:- 1473-4877
- Adalimumab -- administration & dosage
- Antirheumatic Agents -- administration & dosage
- Arthritis, Psoriatic -- drug therapy
- Bayes Theorem
- Biological Products -- administration & dosage
- Clinical Trials, Phase III as Topic
- Comparative Effectiveness Research
- Costs and Cost Analysis
- Health Care Costs
- Humans
- Methotrexate -- administration & dosage
- Models, Economic
- Network Meta-Analysis
- Randomized Controlled Trials as Topic
- Thalidomide -- administration & dosage
- Treatment Outcome
No physical items for this record
Publication Type: Comparative Study; Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Review; Systematic Review
There are no comments on this title.
Log in to your account to post a comment.